Novo Nordisk slashes price of anti-obesity drug Wegovy as Lilly's Mounjaro sets sales record in India

In an indication of growing competition in the Indian obesity management market, Novo Nordisk India has announced a 37% price reduction for its weight-loss drug Wegovy (semaglutide). The starting dose of Wegovy (0.25 mg) will now be available at an effective weekly price of ₹2,712. The new price, including that of the device used to administer the drug for the starting dose, will be ₹10,850.

Semaglutide belongs to a class of drugs called GLP-1, which broadly acts as an appetite suppressant and thereby lowers calorie intake. Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in October after its domestic launch in March 2025. Wegovy is yet to show a similar uptick in sales in India.

Wegovy was launched pan-India as a once-weekly, innovative FlexTouch device in five dose strengths—0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg—in June 2025. The company claims Wegovy to be the first and only obesity medication for people with overweight or obesity in India, indicated for both chronic weight management and reduction in cardiovascular risks.

The revised prices for other strengths are ₹3462 for 0.5 mg and 1 mg, and ₹4100 for 1.7 mg and 2.4 mg.

 “Ever since the launch of this innovative chronic weight management medication this year, we have dedicatedly worked towards making it accessible to the maximum number of people living with overweight or obesity in India. We have made sure to listen to our patient and doctor communities and take active measures for the benefit of people at large. Obesity is a serious concern for India, and this price revision underlines our mission to provide quality obesity treatment to Indians, which is effective, safe, convenient and can be sustained in their daily lives,” Vikrant Shrotriya, Managing Director, Novo Nordisk India said.

Earlier this week, Novo Nordisk India announced a partnership with Pune-based Emcure Pharma, under which Emcure will launch semaglutide injection 2.4 mg under the brand name Poviztra to expand the product’s reach in the Indian market.